Bristol Myers Squibb Licenses BridgeBio’s BBP-398 for Cancer
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 5 (Table of Contents)
Published: 31 May-2022
DOI: 10.3833/pdr.v2022.i5.2692 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol Myers Squibb has entered into a licensing agreement with BridgeBio Pharma to develop and commercialise the latter’s SHP2 inhibitor, BBP-398, in oncology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS